Mylan Introduces Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Triple Combo Once-Daily HIV Treatment in the U.S.
HERTFORDSHIRE, England and PITTSBURGH, March 28, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will introduce in the U.S. a third cost-saving HIV combination. The U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 28, 2018 Category: Drugs & Pharmacology Source Type: news
Symfi Lo (Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 22, 2018 Category: Drugs & Pharmacology Source Type: news
Cimduo (Lamivudine and Tenofovir Disoproxil Fumarate Tablets, for Oral Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 21, 2018 Category: Drugs & Pharmacology Source Type: news
Tenofovir Alafenamide Plus Emtricitabine Effective, Safe in HIV Tenofovir Alafenamide Plus Emtricitabine Effective, Safe in HIV
In HIV patients, combination therapy with tenofovir alafenamide and emtricitabine is non-inferior to that of abacavir plus lamivudine, according to a manufacturer-sponsored trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 13, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Tenofovir Fails to Add Extra Hepatitis B Protection for Vaccinated Newborns Tenofovir Fails to Add Extra Hepatitis B Protection for Vaccinated Newborns
Adding tenofovir disoproxil fumarate (TDF) to an aggressive treatment strategy fails to give extra protection to newborns at risk for contracting hepatitis B virus (HBV) from their infected mothers, according to a study at 17 public hospitals in Thailand.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 8, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Antiviral drug not beneficial for reducing mother-to-child transmission of hepatitis B when added to existing preventatives, study shows
(NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development) Tenofovir disoproxil fumarate (TDF), an antiviral drug commonly prescribed to treat hepatitis B infection, does not significantly reduce mother-to-child transmission of hepatitis B virus when taken during pregnancy and after delivery, according to a phase III clinical trial in Thailand funded by the National Institutes of Health. The study tested TDF therapy in addition to the standard preventative regimen -- administration of hepatitis B vaccine and protective antibodies at birth -- to explore the drug's potential effects on mother-to-ch...
Source: EurekAlert! - Infectious and Emerging Diseases - March 7, 2018 Category: Infectious Diseases Source Type: news
Tenofovir Gel Less Effective in Women With Genital Inflammation Tenofovir Gel Less Effective in Women With Genital Inflammation
Tenofovir gel is less effective in preventing HIV in women with genital inflammation, according to a post hoc analysis of data from the CAPRISA 004 study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 6, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Mylan to Introduce Cimduo (lamivudine and tenofovir disoproxil fumarate) as a New Cost-Saving HIV Combination Treatment in the U.S.
HERTFORDSHIRE, England and PITTSBURGH, March 2, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will launch Cimduo, which was approved in February by the U.S. Food and Drug Administration (FDA).... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 2, 2018 Category: Drugs & Pharmacology Source Type: news
Mylan to Introduce Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) as a New Cost-Saving HIV Combination Treatment in the U.S.
HERTFORDSHIRE, England and PITTSBURGH, March 2, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will launch a new HIV treatment, Symfi Lo, which was approved in February by the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 2, 2018 Category: Drugs & Pharmacology Source Type: news
Mylan to Introduce Two New Cost-Saving HIV Combination Treatments in the U.S.
FDA recently approved Symfi Lo, a three-drug single-tablet antiretroviral (ARV) regimen, and Cimduo, a double combination, for HIV treatment
Mylan will launch Symfi Lo and Cimduo at a significant discount to the price of competing products to bring co... Biopharmaceuticals, HIV/AIDS, Product Launch Mylan, Symfi Lo, Cimduo, efavirenz, lamivudine, tenofovir (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 2, 2018 Category: Pharmaceuticals Source Type: news
Monthly News Roundup - February 2018
Gilead ’s Biktarvy Cleared for Use in HIV-1 Infection
In February, the FDA approved Gilead ' s Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide, or BIC/FTC/TAF), a combination, once-daily, oral treatment for HIV-1 infection in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 28, 2018 Category: Pharmaceuticals Source Type: news
Genital inflammation reduces efficacy of tenofovir gel
(Columbia University's Mailman School of Public Health) A new study shows that genital inflammation significantly reduces the effectiveness of tenofovir gel in preventing HIV infection in women. These findings indicate that both genital inflammation and adherence need to be addressed to improve the effectiveness of topical pre-exposure prophylaxis strategies for HIV prevention in women. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 28, 2018 Category: Infectious Diseases Source Type: news
Pharmacokinetics of Tenofovir Vaginal Gel Differs by Age Pharmacokinetics of Tenofovir Vaginal Gel Differs by Age
The pharmacokinetics of tenofovir vaginal gel differs between premenopausal and postmenopausal women, likely because of differences in the state of the cervicovaginal mucosa, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 20, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Biktarvy (Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 14, 2018 Category: Drugs & Pharmacology Source Type: news
New 3-Drug Combo for HIV OK'd
(MedPage Today) -- Gilead ' s Biktarvy includes bictegravir, emtricitabine, and tenofovir alafenamide (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 8, 2018 Category: Primary Care Source Type: news
